Stay updated with breaking news from Retinal Eye. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
UK beauty expert Inge van Lotringen refuses to spend loads of money on stuff that won't make a difference to signs of ageing. Sometimes, 'cheating' is a lot more effective.
More than thirty years after discovering Leber’s hereditary optic neuropathy (LHON) as the first maternally inherited disease associated with homoplasmic mtDNA mutations, we still struggle to achieve effective therapies. LHON is characterized by selective degeneration of retinal ganglion cells (RGCs) and is the most frequent mitochondrial disease, which leads to blindness young people, in particular males. Despite the causative mutations are present in all tissues, yet only a specific cell type is affected. Our deep understanding of the pathogenic mechanisms in LHON is hampered by the lack o...
Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD 04/07/2021 | 11:45am EDT Send by mail : Message : Required fields Oxurion is a leader in the development of pan-RGD integrin antagonists for retinal vascular disorders - THR-687 on track to enter Phase 2 development by mid-year Leuven, BE, Boston, MA, US – April 7, 2021 – 05.45 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care therapies for ...
Oxurion NV - Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD & Corporate Communications wouter.piepers@oxurion.com (mailto:wouter.piepers@oxurion.com) EU Tel: +44 20 7638 9571 oxurion@citigatedewerogerson.com (mailto:thrombogenics@citigatedewerogerson.com) US chris.brinzey@westwicke.com (mailto:chris.brinzey@westwicke.com) About Oxurion Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of ... Oxurion NVApril 7, 2021 GMT Oxurion is a leader in the development of pan-RGD integrin antagonists for retinal vascular disorders - THR-687 on track to enter Phase 2 development by mid-year Leuven, BE, Boston, MA, US – April 7, 2021 – 05.45 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care therapies for retinal vascular disorders, a...